# CVS part 2 colour table

| Disease Name | Organisms | Identification Feature/Morphological Detail | Biotype and method of typing | Virulence Factors | Steps in Pathogenesis and Transmission | Toxins and it's mechanism of action | Clinical Manifestations | Specimen Collection and Transport | Microscopy and Smear Findings/Special Stains | Culture Media/Methods or Motility | Identification and Typing Methods | Detection Methods-Automated and Conventional | Treatment | Vaccines |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dengue | Dengue virus (DENV), an arbovirus from family Flaviviridae. | Enveloped virus containing ssRNA. | Five serotypes: DEN-1, DEN-2, DEN-3, DEN-4, DEN-5. **Genotype detection** by molecular typing (13 genotypes detected so far). | - | **Transmission:** By **Aedes aegypti** (principal vector) and **Aedes albopictus**. Man and Aedes are principal reservoirs. **Pathogenesis:** Primary infection with one serotype. Secondary infection with a different serotype can lead to a more severe form due to **Antibody Dependent Enhancement (ADE)**, where non-neutralizing antibodies from the first infection enhance viral uptake by mononuclear cells, leading to severe disease. | - | **1997 WHO Classification:** 1. Dengue Fever (DF) 2. Dengue Hemorrhagic Fever (DHF) 3. Dengue Shock Syndrome (DSS).  **2009 WHO Classification:** 1. Dengue with/without warning signs 2. Severe Dengue.  **Warning signs include:** Abdominal pain, persistent vomiting, fluid accumulation, mucosal bleed, lethargy, liver enlargement, rising HCT with falling platelets. | Blood, collected from -1 to +5 days of symptom onset for virus detection, or after day 5 for serology. | - | **Virus isolation:** Inoculation into mosquito cell lines (**C6/36**, **AP61**) or mouse. Available in reference centers. | Serotyping and genotyping by Real time RT-PCR. | **Antigen Detection:** NS1 antigen by ELISA and ICT (detectable from day 1). **Antibody Detection:** **MAC-ELISA** (IgM antibody capture ELISA) is the recommended test. ICT also available.  **Molecular:** Real time RT-PCR (most sensitive and specific). | No specific antiviral therapy. Treatment is symptomatic and supportive: Replacement of plasma losses, correction of electrolyte/metabolic disturbances, platelet transfusion if needed. | **Dengue Vaccine (CYD-TDV - Dengvaxia):** Live-attenuated, tetravalent. Licensed for human use since 2015 for ages 9-45. **WHO recommends use only in people previously infected with dengue** due to risk of severe disease in seronegative recipients. |
| Chikungunya | Chikungunya virus, genus Alphavirus, family Togaviridae. | Enveloped virus, containing ssRNA. | Novel mutation **E1-A226V** led to a shift in vector preference to **A. albopictus**. | - | **Transmission:** By **Aedes aegypti** (primarily) and **Aedes albopictus**. Rare vertical transmission or by blood transfusion.  **Transmission cycle:** Maintained through an **urban cycle** (human-Aedes aegypti) and a **sylvan/jungle cycle** (monkeys-forest Aedes). | - | **Acute stage (3-7 days):** Fever and severe joint pain (arthritis), often debilitating ('that which bends up').  **Chronic stage (10-15%):** Joint pain can last for months or years.  **Chik sign:** Rare hyperpigmentation over centrofacial area. Generally less severe than dengue with rare hemorrhagic manifestations. | Blood/Serum. | - | Viral isolation in mosquito cell lines. Takes 1-2 weeks. Available in reference centers. | - | **Antibody Detection:** **MAC (IgM Antibody Capture) ELISA** is the best format. Rapid tests (e.g., ICT) also available.  **Molecular:** Reverse-transcriptase PCR (RT-PCR) to detect specific genes (e.g. nsP1, nsP4). **Hematology:** Leukopenia with lymphocyte predominance, rare thrombocytopenia. | Supportive measures only. No specific antiviral drugs are available. | Vaccine is not available, though trials are ongoing. |
| Kyasanur Forest Disease (KFD) | KFD virus, family Flaviviridae. | Enveloped virus, containing ssRNA. | - | - | **Vector:** Hard ticks (**Haemaphysalis spinigera**).  **Hosts:** Maintained in animal-tick cycles. Monkeys are amplifier hosts. Rodents and squirrels are common hosts. | - | Incubation period 3-8 days.  **First stage (hemorrhagic fever):** Acute high fever, malaise, frontal headaches, bleeding from nose, throat, gums, and GI tract.  **Second stage (7-21 days later):** Meningoencephalitis. | Blood/Serum. | Non-specific findings: Leukopenia, thrombocytopenia, decreased hematocrit, albuminuria, abnormal CSF in second stage. | Virus isolation from blood. | - | **Antibody Detection:** IgM detection by ELISA.  **Molecular:** Nested RT-PCR and real time RT-PCR detecting viral RNA (NS-5 non-coding region). | Only supportive measures. No specific antiviral drugs available. | **Killed KFD Vaccine:** A formalin-inactivated chick embryo vaccine developed at Haffkine institute, Mumbai. Recommended in endemic areas of Karnataka. |
| Filovirus Infections (Ebola Virus Disease) | Ebola virus, Marburg virus (Family Filoviridae). | Pleomorphic, long **filamentous threads** (average size 805 nm for Ebola). | Six Ebola virus species: **Zaire**, Bundibugyo, Sudan, Taï Forest, Reston, and Bombali. Zaire species caused the 2014 West African outbreak. | - | **Reservoir:** Suspected to be fruit bats or primates.  **Transmission:** Introduced to humans via close contact with blood/secretions of infected animals.  **Human-to-human transmission:** Via direct contact (through broken skin/mucous membranes) with blood, secretions, organs, or other body fluids of infected people, or contaminated surfaces. | - | Incubation period 2-12 days. Fever, headache, muscle pain, sore throat, followed by abdominal pain, vomiting, severe watery diarrhea, and a diffuse rash, often leading to shock and death. Highly fatal (25-90%). | Blood, serum, body fluids. Must be handled in BSL-4 conditions. | **Electron microscopy** shows typical filamentous viruses. Immunohistochemical staining can localize viral antigen in tissue. | Virus isolation in **Vero cell line** (requires biosafety level-4). | - | **Antibody Detection:** ELISA for IgM and IgG (using recombinant NP and GP antigens).  **Antigen Detection:** Capture ELISA for NP, VP40, GP proteins.  **Molecular:** RT-PCR and real time RT-PCR to detect specific RNA (NP, GP genes). | Supportive care (rehydration, symptomatic treatment). No proven treatment yet. | No approved vaccine for general use. **rVSV-ZEBOV** vaccine was used in the 2018-2019 DRC outbreak under a trial protocol. |
| Malaria | *Plasmodium vivax, P. falciparum, P. malariae, P. ovale, P. knowlesi*. | Multiple morphological stages in humans: **Ring form** (early trophozoite), amoeboid trophozoite, **Schizont** (rosette), **Gametocyte** (crescent/banana-shaped in *P. falciparum*). | Speciation based on morphology in thin smears. Nested PCR can differentiate species. | ***P. falciparum* Virulence:** Sequestration mediated by **PfEMP-1** (P. falciparum erythrocyte membrane protein-1), which facilitates **cytoadherence** (binding of infected RBCs to endothelial cells) and **rosetting** (binding to uninfected RBCs). Antigenic variation of PfEMP-1 helps evade immune response. | **Transmission:** Bite of female **Anopheles mosquito**. Rare transmission via blood transfusion.  **Pathogenesis:** Pre-erythrocytic (hepatic) stage -> Erythrocytic stage. Rupture of RBCs releases merozoites, toxins, and pigments, causing febrile paroxysms. **Relapse** in *P. vivax/ovale* due to dormant **hypnozoites**. **Recrudescence** in *P. falciparum/malariae* due to persistence of parasites. | Toxins released upon RBC rupture contribute to fever and inflammatory response. | **Febrile paroxysm:** Triad of cold stage, hot stage, and sweating stage. Anemia, splenomegaly.  **Severe Malaria (*P. falciparum*):** Cerebral malaria, blackwater fever, pulmonary edema, renal failure, severe anemia, acidosis, hypoglycemia. | Peripheral blood, collected by finger prick (capillary blood). | **Peripheral blood smear (gold standard):**  **Thick smear:** For detection (more sensitive).  **Thin smear:** For speciation.  **Stains:** Leishman's, Giemsa, Field's, JSB.  **Fluorescence microscopy (Kawamoto's technique)** with acridine-orange. | **Trager and Jensen method** using **RPMI 1640 medium**. Used for research (e.g., drug susceptibility), not routine diagnosis. | Speciation by thin smear morphology. Molecular methods like nested multiplex PCR targeting 18S rDNA can identify all five species. | **Rapid Diagnostic Tests (RDTs):** Detect antigens like HRP-II (*P. falciparum* specific), pLDH, or aldolase.  **Quantitative Buffy Coat (QBC):** Centrifugation of blood in acridine orange-coated tube, viewed under UV light. | **Uncomplicated:** Chloroquine + Primaquine for *P. vivax*. Artemisinin-based Combination Therapy (ACT) for *P. falciparum*.  **Severe Malaria:** IV Artesunate or IV Quinine. | **RTS,S/AS01 (Mosquirix):** The only vaccine candidate that has completed phase III trials. It is a pre-erythrocytic vaccine targeting the circumsporozoite protein (CSP) of *P. falciparum*. |
| Babesiosis | *Babesia microti* (most common), *B. bovis, B. divergens*. | Ring forms inside RBCs arranged in pairs or tetrads, known as **Maltese cross forms**. Lack of pigments and crescentic gametocytes differentiates it from *P. falciparum*. | - | - | **Transmission:** By the bite of a hard tick (**Ixodes scapularis**).  **Pathogenesis:** Similar to malaria but no liver stage; sporozoites enter RBCs directly. | - | Malaria-like illness. Less severe anemia and no periodicity in fever cycle. More severe in splenectomized and immunocompromised patients. | Peripheral blood. | **Peripheral blood smear** (Giemsa stained) examination reveals characteristic **Maltese cross forms**. | - | - | Microscopy is the primary method of diagnosis. | Atovaquone plus azithromycin. | - |
| Visceral Leishmaniasis (Kala-azar) | *Leishmania donovani* complex. | Dimorphic protozoa. **Amastigote (LD body):** Diagnostic form in humans; round/oval, non-motile, found inside macrophages. **Promastigote:** Infective stage in sandfly; lanceolate, motile. | - | - | **Transmission:** Bite of female **sandfly** vector.  **Pathogenesis:** Promastigotes are phagocytosed by macrophages, transform into amastigotes, multiply, and infect other cells of the reticuloendothelial system. | - | Fever, weight loss, massive splenomegaly, hepatomegaly, pancytopenia, hypergammaglobulinemia. Can be followed by **Post-kala-azar dermal leishmaniasis (PKDL)**. | Bone marrow aspirate, spleen aspirate (highest yield but risky), lymph node aspirate, peripheral blood buffy coat. | **Giemsa-stained smears** of aspirates to demonstrate **LD bodies (amastigotes)** within macrophages. This is the gold standard. | Culture of aspirate on **NNN (Novy-MacNeal-Nicolle) medium** or Schneider's insect medium. Promastigotes develop. | **Montenegro skin test** (Leishmanin test) for cell-mediated immunity (negative in active VL, positive after cure). | **Serology:** Aldehyde test, Antimony test (non-specific). Specific tests include DAT, ELISA, and ICT using **rk39 antigen**.  **Molecular:** PCR. | Liposomal Amphotericin B is the drug of choice. Miltefosine (oral). Pentavalent antimonials are now less used due to resistance. | - |
| Trypanosomiasis | **African (Sleeping Sickness):** *Trypanosoma brucei gambiense, T. b. rhodesiense*.  **American (Chagas' Disease):** *Trypanosoma cruzi*. | **Trypomastigote:** Diagnostic C- or S-shaped form in blood.  **Amastigote:** (*T. cruzi* only) Round, non-flagellated form in tissue (e.g., heart muscle). | - | - | **African:** Transmitted by **Tsetse fly**.  **American:** Transmitted by feces of **Reduviid bug** (kissing bug).  Pathogenesis involves replication in blood (African) or tissue (American), leading to systemic disease. | - | **African:** Chancre -> Hemolymphatic stage (fever, **Winterbottom's sign**) -> Meningoencephalitic stage (somnolence).  **American:** Acute phase (fever, **Romana's sign**) -> Chronic phase (cardiomyopathy, megaesophagus, megacolon). | Blood, lymph node aspirate, CSF (African). Blood (American). | Microscopic examination of wet mount or Giemsa-stained thick/thin blood smears for trypomastigotes. | - | **Xenodiagnosis** (for Chagas' disease): Lab-reared reduviid bugs are fed on the patient, and their feces are later examined for parasites. | **Serology** (especially for chronic Chagas' disease). Card Agglutination Test for Trypanosomiasis (CATT) for African sleeping sickness screening. | **African:** Pentamidine/Suramin (early), Melarsoprol/Eflornithine (late).  **American:** Benznidazole, Nifurtimox. | - |
| Lymphatic Filariasis (Bancroftian) | *Wuchereria bancrofti* | **Adult worms:** In lymphatics. **Microfilariae:** In peripheral blood (diagnostic stage), **sheathed**, body curves are graceful and sweeping, tail tip is tapered and **free of nuclei**. | Exhibits **nocturnal periodicity** in most endemic areas (microfilariae appear in peripheral blood at night). | - | **Transmission:** Bite of mosquitoes (**Culex**, **Anopheles**, **Aedes**).  **Pathogenesis:** Adult worms in lymphatics cause obstruction and inflammation, leading to lymphatic damage and subsequent edema. | - | **Acute:** Adenolymphangitis (ADL), filarial fever.  **Chronic:** Lymphedema, **elephantiasis** (legs, scrotum, arms), **hydrocele**, chyluria.  **Occult:** **Tropical pulmonary eosinophilia (TPE)**. | Peripheral blood collected between 10 PM and 2 AM. Hydrocele fluid. Urine (for chyluria). | **Thick blood smear** stained with Giemsa or Leishman stain to demonstrate microfilariae. **QBC** can detect motile microfilariae. | Motility of microfilariae observed in wet mount or QBC. | **Membrane filtration technique** to concentrate microfilariae from a larger volume of blood. | **Antigen detection:** **Immunochromatographic card test (ICT)** detects circulating filarial antigen (CFA) of *W. bancrofti*.  **Ultrasound:** Can show motile adult worms in lymphatics (**filarial dance sign**). | **Diethylcarbamazine (DEC)** is the drug of choice. Mass Drug Administration (MDA) with DEC and Albendazole, or Ivermectin and Albendazole. | - |
| Lymphatic Filariasis (Brugian) | *Brugia malayi, B. timori* | **Microfilariae:** In peripheral blood, **sheathed**, body curves are kinky and irregular, tail has **two distinct terminal nuclei**. | Nocturnal periodicity. | - | **Transmission:** Bite of **Mansonia** mosquitoes. Zoonotic potential with animal reservoirs. | - | Similar to Bancroftian filariasis, but elephantiasis is typically restricted to below the knee. Genital involvement and chyluria are rare. | Peripheral blood collected at night. | Thick blood smear stained with Giemsa. | - | - | Antigen detection tests (ICT) are not available for *Brugia*. Diagnosis relies on microscopy and clinical picture. | Diethylcarbamazine (DEC). | - |
| Systemic Candidiasis | *Candida albicans*, *C. tropicalis*, *C. parapsilosis*, *C. glabrata*, *C. auris*. | Polymorphic: Exists as budding yeast, pseudohyphae, and true hyphae. *C. albicans* forms **germ tubes** in serum at 37°C. | Speciation by **Chromogenic agar**, automated systems (VITEK), or MALDI-TOF. | Adhesins, aspartyl proteinases, phospholipases, **phenotypic switching**, **biofilm formation**. | Endogenous infection from normal flora. Risk factors: Immunosuppression, prolonged antibiotic/steroid use, IV catheters, TPN, neutropenia. Pathogen enters bloodstream (candidemia) and disseminates. | - | **Candidemia:** Fever, sepsis.  **Disseminated candidiasis:** Infection of various organs, e.g., endophthalmitis, renal abscesses, endocarditis, CNS infection. | Blood, sterile body fluids, catheter tips. | Gram stain shows Gram-positive budding yeast cells and pseudohyphae. | Grows readily on most media. **Sabouraud Dextrose Agar (SDA)**: Creamy, pasty, white colonies. Blood culture on automated systems (e.g., BACTEC). | **Germ tube test** for *C. albicans*. Corn meal agar for chlamydospore production. Sugar assimilation/fermentation tests. | **Blood culture** is the gold standard.  **Beta-D-glucan assay** (non-specific biomarker).  **PNA-FISH**, MALDI-TOF for rapid identification from positive blood cultures. | **Echinocandins** (e.g., Caspofungin) are first-line for candidemia. Fluconazole (if susceptible). Liposomal Amphotericin B for severe infections. | - |
| Histoplasmosis | *Histoplasma capsulatum* | Thermally dimorphic fungus. **Mold phase (25°C):** Septate hyphae with microconidia and characteristic large, thick-walled, tuberculate macroconidia. **Yeast phase (37°C):** Small, oval budding yeast cells, often found intracellularly in macrophages. | - | Ability to survive and multiply within macrophages. | **Transmission:** Inhalation of microconidia from soil enriched with bird or bat droppings.  **Pathogenesis:** Conidia convert to yeast in lungs, are phagocytosed by macrophages, and disseminate via bloodstream to reticuloendothelial system. | - | >90% asymptomatic.  **Pulmonary histoplasmosis:** Acute (flu-like) or chronic (cavitary disease).  **Progressive disseminated histoplasmosis (PDH):** In immunocompromised patients, affects liver, spleen, bone marrow. | Sputum, bronchoalveolar lavage (BAL), tissue biopsy, blood, bone marrow aspirate. | **Giemsa or Wright stain** of bone marrow/blood shows small intracellular budding yeast cells. GMS or PAS stain for tissue biopsy. | Culture on **SDA** (for mold form) or BHI agar with blood (for yeast form). Slow growing (2-4 weeks). | Conversion of mold to yeast form by incubation at 37°C confirms dimorphism. Exoantigen test or DNA probes for definitive identification. | **Culture is gold standard.** **Antigen detection** (in urine or serum) is useful for diagnosis of PDH.  **Serology:** Complement fixation and immunodiffusion (detects H and M bands). | **Itraconazole** for mild to moderate disease. **Liposomal Amphotericin B** for severe or disseminated disease. | - |
| Blastomycosis | *Blastomyces dermatitidis* | Thermally dimorphic fungus. **Mold phase (25°C):** White, cottony mold. **Yeast phase (37°C):** Large, spherical, thick-walled multinucleated yeast cell with a characteristic single **broad-based bud**. | - | - | **Transmission:** Inhalation of conidia from disturbed soil or decaying wood.  **Pathogenesis:** Primary infection in lungs, can disseminate hematogenously to other sites, especially skin and bone. | - | **Pulmonary blastomycosis:** Can be asymptomatic, acute (pneumonia-like), or chronic.  **Extrapulmonary disease:** Most commonly involves skin (verrucous or ulcerative lesions) and bones (osteomyelitis). | Sputum, BAL, pus from skin lesions, tissue biopsy. | Direct microscopy (KOH mount or stained smear) shows large, thick-walled yeast cells with **broad-based budding**. | Culture on **SDA** at 25°C shows mold form. Conversion to yeast form at 37°C for confirmation. | Exoantigen test or DNA probes for definitive identification. | **Culture is the gold standard.** Microscopy is highly suggestive. Antigen/antibody tests are available but have significant cross-reactivity. | **Itraconazole** for mild to moderate disease. **Amphotericin B** for severe, life-threatening, or CNS disease. | - |
| Coccidioidomycosis (Valley Fever) | *Coccidioides immitis, C. posadasii* | Dimorphic fungus (but no yeast phase). **Mold phase (25°C):** Septate hyphae that fragment into highly infectious barrel-shaped **arthroconidia**. **Tissue phase (37°C):** Large, thick-walled, non-budding **spherules** containing numerous endospores. | - | - | **Transmission:** Inhalation of airborne arthroconidia from dry, alkaline soil of desert regions.  **Pathogenesis:** Arthroconidia convert to spherules in the lungs. Spherules rupture to release endospores, which can disseminate. | - | 60% asymptomatic.  **Acute pulmonary coccidioidomycosis (Valley Fever):** Flu-like illness. Can have allergic reactions like erythema nodosum.  **Disseminated disease:** Can spread to skin, bones, joints, and meninges. | Sputum, BAL, CSF, tissue biopsy. | Direct microscopy (KOH mount, H&E, GMS, PAS) to demonstrate characteristic **spherules** with endospores. | Culture on **SDA**. Highly infectious mold, must be handled in a **biosafety level 3 (BSL-3)** cabinet. | DNA probe for definitive identification of culture. | Microscopy, Culture, and **Serology** are key.  **Serology:** Tube precipitin test for IgM (early), complement fixation for IgG (later, and for prognosis). | Most acute cases are self-limiting. **Fluconazole or Itraconazole** for symptomatic disease. **Amphotericin B** for severe or disseminated disease. | - |
| Paracoccidioidomycosis | *Paracoccidioides brasiliensis* | Thermally dimorphic fungus. **Mold phase (25°C):** Non-descript septate hyphae. **Yeast phase (37°C):** Large, spherical to oval, thick-walled yeast cell with characteristic multiple buds, forming a **"Mariner's wheel"** or "Mickey Mouse" appearance. | - | - | **Transmission:** Inhalation of conidia from soil.  **Pathogenesis:** Primary infection in lungs, often latent for years. Reactivation leads to chronic granulomatous disease, with frequent dissemination to mucocutaneous sites. | - | **Chronic progressive disease:** Pulmonary involvement and ulcerative granulomatous lesions of the mucosa of the mouth, nose, and sometimes GI tract. Lymph node involvement is common. | Sputum, pus, or scrapings from mucocutaneous lesions, tissue biopsy. | Direct microscopy (KOH mount) of clinical specimens reveals the characteristic large, multiple-budding yeast cells (**Mariner's wheel**). | Culture on BHI agar with blood at 37°C (for yeast form) or SDA at 25°C (for mold form). Slow growing. | - | Microscopy and culture are definitive. **Serology** (immunodiffusion) is highly specific and useful for diagnosis and monitoring treatment. | **Itraconazole** is the drug of choice for most forms. Sulfonamides can be used as an alternative. **Amphotericin B** for severe cases. | - |